What to Do With Your CAC Results

Introduction

A CAC score provides information. Converting that information into appropriate action requires understanding how the result fits with other clinical factors. A high score in an otherwise healthy person means something different than the same score in someone with diabetes and hypertension.

Guidelines provide general frameworks, but individual decisions involve nuance. This article addresses common questions about translating CAC results into treatment decisions: medication thresholds, lifestyle modifications, additional testing, and how to synthesize CAC with other risk information.

For information on understanding your score, see How to Interpret Your CAC Score. For comparison with other tests, see CAC vs Other Cardiac Tests.

How should a non-zero CAC score change your treatment plan?

Any calcium above zero confirms the presence of atherosclerosis. This shifts the clinical context from primary prevention of disease that might develop to secondary prevention of events from disease already present. The conversation changes from “should we prevent atherosclerosis?” to “how aggressively should we treat the atherosclerosis we know exists?”

Most clinicians will recommend statin therapy for patients with CAC above 100, and many will recommend it for any score above zero depending on other risk factors. The 2019 ACC/AHA guidelines indicate that CAC of 1-99 favors statin therapy, while CAC ≥100 and especially ≥300 substantially support statin use (Arnett et al., 2019).

Beyond medication, a non-zero score should motivate intensive lifestyle optimization. Diet, exercise, blood pressure control, and smoking cessation become more urgent when you know atherosclerosis is present rather than theoretical.

At what score threshold do guidelines recommend starting statins?

Guidelines do not specify a rigid threshold but provide interpretive guidance. A score of zero in someone without other risk-enhancing factors supports deferring statin therapy. Scores of 1-99 favor statin therapy, particularly if the percentile is elevated for age. Scores of 100-299 indicate definite atherosclerosis where statin therapy is reasonable. Scores ≥300 strongly support statin use.

Large cohort studies demonstrate progressively increasing event rates at higher CAC categories, supporting more aggressive prevention at higher scores (Grandhi, 2020). A person with CAC ≥400 has a risk profile comparable to established coronary disease and should generally receive treatment accordingly.

The CAC result should be integrated with other factors, not viewed in isolation. A modest score with elevated Lp(a) and strong family history may warrant more aggressive treatment than a higher score in someone with no other risk factors.

Does a zero score mean you can avoid preventive medications?

A zero score substantially reduces short-term event risk and can reasonably support deferring statin therapy in patients without other compelling indications. The CAC Consortium data showed very low event rates in people with zero calcium, even among those with multiple traditional risk factors (Grandhi, 2020).

However, a zero score does not guarantee safety. Studies confirm that some patients with zero calcium have non-calcified plaque (Ergün et al., 2011). Patients with diabetes, very high LDL, or other compelling indications may warrant statin therapy regardless of calcium score.

The appropriate interpretation is that a zero score allows a more personalized approach, potentially deferring medication in favor of aggressive lifestyle modification with periodic reassessment. It does not justify ignoring other risk factors entirely.

How does CAC scoring inform decisions about aspirin therapy?

Aspirin for primary prevention has become more controversial as studies showed modest benefit offset by bleeding risk. The 2019 ACC/AHA guidelines de-emphasized routine aspirin in primary prevention but noted it might be considered for those at higher risk without increased bleeding risk (Arnett et al., 2019).

CAC can help identify individuals whose atherosclerotic burden might tip the benefit-risk balance toward aspirin use. Someone with a CAC score above 100-300 has demonstrated coronary disease where aspirin’s antiplatelet effects might be more relevant than in someone with zero calcium.

Aspirin decisions should involve discussion with a physician who can assess individual bleeding risk and preferences. CAC provides one input into this complex calculation but does not dictate aspirin use in isolation.

Should a high CAC score trigger additional testing?

A high score indicates extensive atherosclerosis but does not reveal whether any lesion causes significant stenosis or ischemia. Additional testing may be appropriate depending on symptoms, score magnitude, and treatment implications.

Asymptomatic patients with high CAC (≥300-400) might benefit from stress testing to assess functional significance. If ischemia is present, more aggressive management including possible coronary angiography might be warranted. In the absence of symptoms or ischemia, aggressive medical therapy without further anatomic testing is reasonable.

CT angiography can provide detailed anatomy in patients where knowing stenosis severity would change management. If a patient with a very high CAC would undergo revascularization for significant stenosis, CCTA can identify those lesions noninvasively.

How do you balance CAC results against other risk factors in treatment decisions?

CAC is one input among many. It should be integrated with family history, lipid profile, blood pressure, metabolic status, genetic markers (if available), and patient preferences. No single factor dictates treatment.

Consider a patient with moderate CAC (150) but excellent lipid profile, no family history, and strong preference to avoid medication. This differs from someone with the same CAC but elevated Lp(a), family history of premature disease, and high LDL. The former might reasonably pursue aggressive lifestyle modification with close monitoring; the latter clearly warrants pharmacotherapy.

Shared decision-making matters. CAC provides objective information that helps patients understand their actual disease state. Some patients find visual evidence of calcium more motivating than abstract risk percentages. Others may feel anxious about any positive finding. Discussing implications honestly while respecting preferences leads to sustainable treatment plans.

What lifestyle interventions are most evidence-based for someone with elevated CAC?

The same lifestyle interventions that prevent atherosclerosis development also benefit those with established disease. Diet patterns emphasizing plants, whole grains, lean proteins, and healthy fats consistently show cardiovascular benefit. Mediterranean and DASH dietary patterns have the strongest evidence base.

Exercise provides benefit even in those with high CAC. Active individuals have better outcomes than sedentary ones at any CAC level (Arnson, 2017). The CAC-mortality relationship persists but is attenuated by physical activity, suggesting exercise confers protection beyond what the calcium score alone would predict.

Blood pressure optimization, smoking cessation, and weight management round out lifestyle priorities. For patients with elevated CAC, these become treatment imperatives rather than theoretical recommendations. The presence of proven disease raises the stakes.

Conclusion

Translating a CAC score into action involves integrating the result with other clinical information and patient preferences. High scores generally warrant aggressive prevention including statin therapy. Zero scores may support a more conservative approach, particularly in the absence of other risk-enhancing factors.

The score provides objective evidence about whether atherosclerosis exists and how extensive it is. This information empowers informed decisions about medication, lifestyle intensity, and additional testing. For guidance on obtaining a scan, see How to Get a CAC Scan If Your Doctor Doesn’t Suggest One.